Shukra Pharmaceuticals clears its NSE listing formalities

NSE has admitted Shukra Pharmaceuticals to listing. The listing date will follow in a separate circular.

Shukra Pharmaceuticals Secures BSE Approval for Listing of New Equity Shares

Shukra Pharmaceuticals Limited has recently achieved a significant corporate milestone. The Bombay Stock Exchange (BSE) has officially issued a notice permitting the listing and trading of new equity shares of the company. The shares officially commenced trading on the exchange with effect from Tuesday, August 4, 2026.

Key Details of the New Listing The recent listing involves a substantial block of shares issued directly to the company's promoters. Here are the core details of the newly listed securities:

Total Shares Listed: 17,35,000 equity shares
Face Value: ₹1 per share
Premium: ₹34.56 per share
Issue Price: ₹35.56 per share
Allotment Date: May 7, 2026
ISIN: INE551C01044

These 17.35 lakh shares were issued on a preferential basis to the promoters pursuant to the conversion of warrants.

Pari-Passu Status and Lock-in Period According to the official circular, the newly listed equity shares will rank pari-passu (on equal footing) with the company's existing equity shares. This means they will carry the same rights, including voting and dividend entitlements, as the older shares. The BSE notice also clarified that there are no lock-in details applicable to these specific shares.

Stellar Q1 FY27 Financial Performance The market is closely watching the company’s financial performance following this listing. On August 12, 2026, the company's Board of Directors met to consider and approve the financial results for the quarter ended June 30, 2026 (Q1 FY27).

The company reported robust growth: Revenue Surge: Standalone revenue from operations for Q1 FY27 reached ₹24.06 crore (₹2,406.20 lakhs), a significant jump from ₹6.50 crore (₹650.08 lakhs) in Q1 FY26. Profitability: Standalone net profit for Q1 FY27 surged to ₹15.02 crore (₹1,502.98 lakhs), compared to just ₹1.02 crore (₹102.96 lakhs) in the same quarter last year.

With its expanding operations in the Pharmaceuticals and MedTech segments, Shukra Pharmaceuticals (BSE Scrip Code: 524632) continues to attract investor attention.